Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2017

Conditions
Chronic Urticaria
Interventions
BIOLOGICAL

Omalizumab

"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"

BIOLOGICAL

Placebo

"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"

Trial Locations (4)

31008

Clinica Universitaria de Navarra, Pamplona

48013

Hospital de Basurto, Bilbao

01004

Hospital Santiago Apostol, Vitoria-Gasteiz

08036

Hospital Clinic, Barcelona

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Hospital Universitario Central de Asturias

OTHER

collaborator

Gregorio Marañón Hospital

OTHER

collaborator

Hospital Universitari Joan XXIII de Tarragona.

OTHER

collaborator

Complejo Hospitalario de Navarra

OTHER

collaborator

Hospital Vall d'Hebron

OTHER

collaborator

Hospital Clínico Universitario Lozano Blesa

OTHER

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER

NCT01713725 - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria | Biotech Hunter | Biotech Hunter